Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07069972

A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.

The objective of this observational study is to compare the efficacy and safety of telitacicept versus belimumab in systemic lupus erythematosus (SLE) patients aged 18-65 years. The primary questions it aims to answer are:

* In the overall SLE population: What are the SRI-4 response rates for both drugs? * In the lupus nephritis subgroup: What are the major renal response rates for both drugs?

Participants will autonomously select their treatment regimen (add-on telitacicept or belimumab) based on:

* The patient's objective clinical condition at enrollment * Physician's assessment * Joint decision-making between physicians and patients/family members As an observational study, no active intervention will be implemented.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Systemic Lupus Erythematosus Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Lupus Erythematosus, Systemic Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age range: 18 - 65 years old;
  • Meets the revised SLE classification criteria of the American College of Rheumatology in 1997 or the SLE diagnostic classification criteria issued by EULAR/ACR in 2019;
  • The SELENA-SLEDAI score is at least 8 points (clinical symptoms are no less than 6 points, excluding positive anti-double-stranded DNA (anti-dsDNA) and low complement);
  • Has not responded well to hormone and/or immunosuppressant treatment, is intolerant or has recurrence, and is willing to accept tixocortinib/belimumab as a therapeutic drug.

Exclusion criteria

  • Any of the following conditions exists: active central nervous system disease, severe active lupus nephritis, HIV infection, hepatitis B or C virus infection, low gamma globulinemia, liver dysfunction;
  • eGFR < 30 mL/min/1.73m², or undergoing hemodialysis or kidney transplantation;
  • Pregnant women, or women who are about to become pregnant in the near future, or lactating women;
  • Participants who are simultaneously participating in other clinical studies;
  • Within 1 year before randomization, received B-cell targeted therapy (including belimumab);
  • During treatment, used traditional Chinese medicine with immunosuppressive effects (such as Tripterygium wilfordii, White Peony Root, etc.) in combination.

Treatment and study plan

Primary outcomes

  1. The percentage of patients with a Systemic Lupus Erythematosus Response Index-4 (SRI-4) response(the overall SLE population)

    Time frame: From baseline to the end of 2-year treatment period

    • A reduction of ≥ 4 points in the SELENA-SLEDAI score from baseline;
    • And no new BILAG A-level organ or ≤ 2 new BILAG B-level organs compared to baseline;
    • And no worsening in the physician's global assessment (PGA) (an increase of < 0.30 points from baseline).

  2. The response rate for major kidney treatments(the lupus nephritis subgroup)

    Time frame: From baseline to the end of 2-year treatment period

    • 24-hour urine PCR ≤ 0.7 g/g (70 mg/mmol);
    • eGFR decline does not exceed 20% of the baseline or is ≥ 60 ml/min/1.73 m2;
    • No rescue treatment was adopted due to treatment failure.

Secondary outcomes

  1. Complete renal response rate(the lupus nephritis subgroup)

    Time frame: From baseline to the end of 2-year treatment period

    • 24-hour urine PCR < 0.5 g/g (50 mg/mmol);
    • Stable or improved renal function (not exceeding 10% - 15% of the baseline).

  2. Proportion of Participants with Stable SLEDAI and PGA Scores(the overall SLE population)

    Time frame: From baseline to the end of 2-year treatment period

    The percentage of study participants whose SLEDAI score decreased by at least 4 points and whose PGA did not worsen.

  3. The proportion of participants in the study who had their hormone dosage reduced(the overall SLE population)

    Time frame: From baseline to the end of 2-year treatment period

    The ratio of study participants whose prednisone dose was reduced by ≥25% or ≤7.5 mg/day compared to the baseline at 44-48 weeks.

  4. The time of recurrence occurrence(the overall SLE population)

    Time frame: From baseline to the end of 2-year treatment period.

    The time of the first recurrence or the first severe recurrence.

Study contacts

Contact information is provided by the study sponsor or research team.

Yipeng Liu

CONTACT

[email protected]

13064089262

Sponsors and collaborators

Lead sponsor

Yipeng Liu

Other

Collaborators

  • Affiliated Hospital of Shandong University of Traditional Chinese Medicine
  • Renmin Hospital of Wuhan University

Registry information

Official study title

Comparing Efficacy and Safety of Telitacicept and Belimumab in Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study.

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jul 17, 2025
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.